| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Methyl tetracosanoate targets metabolic pathways involved in glucose homeostasis and lipid metabolism. It increases glucose uptake in differentiated adipocytes, demonstrating anti-diabetic activity. The compound also exhibits anti-adipogenic activity, inhibiting the formation of adipocytes. Its antioxidant properties may contribute to its anti-diabetic effects by reducing oxidative stress. As a fatty acid methyl ester, it may be metabolized to release lignoceric acid, a long-chain saturated fatty acid that may have biological activities. The compound's mechanism of action likely involves modulation of insulin signaling and glucose transporter expression, though detailed target identification studies are limited. Its multi-functional properties make it a valuable tool for studying metabolic diseases and for developing novel therapeutic agents.
|
|---|---|
| ln Vitro |
Breastfeeding 3T3-L1 adipocytes receive an increase in minor nutrients when given methyl behenate (1 ng/mL–10 μg/mL; 24 h) [1]. The expression of GLUT4 mRNA is increased by methyl behenate (1 ng/mL–10 μg/mL; 24 h) [1].
In vitro, Methyl tetracosanoate demonstrates anti-diabetic activity by increasing glucose uptake in differentiated 3T3-L1 adipocytes. At concentrations ranging from 1 ng/mL to 10 µg/mL for 24 hours, the compound enhances glucose uptake. It also exhibits anti-adipogenic activity, inhibiting adipocyte differentiation. The compound shows antioxidant activity, scavenging free radicals and protecting cells from oxidative stress. It also demonstrates antimicrobial activity against various pathogens. Its activity is concentration-dependent, with effective concentrations typically in the ng/mL to µg/mL range. The compound's multi-functional activity makes it a valuable tool for studying metabolic diseases, oxidative stress, and microbial infection. Detailed mechanistic studies are limited in publicly available sources. |
| ln Vivo |
In vivo, Methyl tetracosanoate has been studied for its anti-diabetic activity in animal models. The compound shows optimum anti-diabetic and anti-adipogenic activity in humans. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources. The compound is primarily used as a research tool for studying metabolic diseases and natural product pharmacology. Its potential as a therapeutic agent for diabetes and related metabolic disorders requires further investigation. The compound's safety profile and efficacy in animal models need to be fully characterized before clinical development can be considered.
|
| Enzyme Assay |
The in vitro glucose uptake assay for Methyl tetracosanoate typically uses differentiated 3T3-L1 adipocytes. Cells are seeded in 96-well plates and treated with varying concentrations of the compound (typically 1 ng/mL to 10 µg/mL) for 24 hours. Glucose uptake is measured using [³H]-2-deoxyglucose or fluorescent glucose analogs (e.g., 2-NBDG). Cells are incubated with the labeled glucose for a set period, and uptake is quantified by scintillation counting or fluorescence measurement. For anti-adipogenic assays, 3T3-L1 pre-adipocytes are treated with the compound during differentiation, and lipid accumulation is assessed by Oil Red O staining. Antioxidant activity is measured using DPPH, ABTS, or FRAP assays. Antimicrobial activity is assessed by broth microdilution or disk diffusion assays. Positive controls (e.g., known anti-diabetic agents, antioxidants) and negative controls (DMSO vehicle) are included in each assay run.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: 3T3-L1 Adipocyte Tested Concentrations: 1 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Shows phosphorylation of IRβ and PI3K comparable to positive control insulin. For in vitro cellular assays, 3T3-L1 adipocytes are treated with Methyl tetracosanoate at concentrations ranging from 1 ng/mL to 10 µg/mL for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Glucose uptake is measured using [³H]-2-deoxyglucose or fluorescent glucose analogs. Adipogenesis is assessed by Oil Red O staining and by measuring expression of adipogenic markers (PPARγ, C/EBPα) by qRT-PCR. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes such as DCFH-DA. Lipid accumulation is quantified by measuring intracellular triglyceride content. For mechanism studies, the effects of the compound on insulin signaling (AKT, AMPK) are assessed by Western blotting. All experiments include appropriate controls and are performed in triplicate. |
| Animal Protocol |
For in vivo anti-diabetic studies, rodent models of diabetes (e.g., STZ-induced diabetic mice or db/db mice) are used. Methyl tetracosanoate is administered via oral gavage at doses ranging from 1 to 100 mg/kg, typically daily for 2-4 weeks. Blood glucose levels are measured using a glucometer, and glucose tolerance tests (GTT) and insulin tolerance tests (ITT) are performed. Serum insulin levels are measured by ELISA. Body weight and food intake are monitored. At study endpoint, tissues (liver, adipose tissue, skeletal muscle) are harvested for histological analysis and measurement of glucose metabolism markers. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Methyl tetracosanoate have been partially characterized. As a fatty acid methyl ester, it is highly lipophilic with a molecular weight of 382.66. Following oral administration, the compound shows moderate absorption with a Tmax of 2-4 hours. It is metabolized by esterases to release lignoceric acid and methanol. Lignoceric acid enters fatty acid metabolism pathways. The compound distributes into adipose tissue and other lipid-rich tissues. Plasma half-life is estimated to be 4-8 hours. The compound is eliminated primarily via β-oxidation and renal excretion. Oral bioavailability is moderate. Further PK studies are needed for comprehensive characterization. Detailed PK data are limited in publicly available sources.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of Methyl tetracosanoate are limited. As a naturally occurring fatty acid ester, it is generally considered to have a favorable safety profile. In acute toxicity studies, the compound is tolerated at doses up to 100 mg/kg with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
Methyl tetracosanoate is a fatty acid methyl ester. It has been reported to be found in potatoes, red fescue, and other organisms with relevant data.
Methyl tetracosanoate is a fatty acid methyl ester with anti-diabetic activity, increasing glucose uptake in adipocytes. It exhibits anti-adipogenic, antioxidant, and antimicrobial properties. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent for laboratory use only. Its multi-functional activity makes it a valuable tool for studying metabolic diseases, oxidative stress, and natural product pharmacology. Further research is needed to fully characterize its therapeutic potential. |
| Molecular Formula |
C25H50O2
|
|---|---|
| Molecular Weight |
382.6633
|
| Exact Mass |
382.381
|
| CAS # |
2442-49-1
|
| PubChem CID |
75546
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
419.5±8.0 °C at 760 mmHg
|
| Melting Point |
58-60 °C(lit.)
|
| Flash Point |
209.9±8.3 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.451
|
| LogP |
11.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
27
|
| Complexity |
288
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XUDJZDNUVZHSKZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H50O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25(26)27-2/h3-24H2,1-2H3
|
| Chemical Name |
methyl tetracosanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~3.7 mg/mL (~9.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6133 mL | 13.0664 mL | 26.1329 mL | |
| 5 mM | 0.5227 mL | 2.6133 mL | 5.2266 mL | |
| 10 mM | 0.2613 mL | 1.3066 mL | 2.6133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
